Best Canadian Stocks To Invest In 2019

&l;p&g;The stock price of Canadian cannabis producer Cronos Group (TSE:CRON) has seen a stellar run over the last year, rising from levels of roughly CAD 1.80 in June 2017 to about CAD 9 currently. The uptick in the stock price has been driven partly by Canada&a;rsquo;s move to legalize cannabis for adult consumers for recreational purposes and a booming medical marijuana market in Canada. Since this is a relatively new industry, it does have the potential to grow and over time become an established and profitable industry such as the tobacco industry. Consequently, investors may currently be anticipating Canadian cannabis stocks to perform better than the more mature tobacco giants, &l;a href=&q;http://finapps.forbes.com/finapps/jsp/finance/compinfo/CIAtAGlance.jsp?tkr=pm&a;amp;tab=searchtabquotesdark&q; target=&q;_blank&q;&g;Philip Morris&l;/a&g; and &l;a href=&q;http://finapps.forbes.com/finapps/jsp/finance/compinfo/CIAtAGlance.jsp?tkr=mo&a;amp;tab=searchtabquotesdark&q; target=&q;_blank&q;&g;Altria&l;/a&g;. In this note, we take a look at some of the factors driving Cronos Group&a;rsquo;s performance and stock price.

Best Canadian Stocks To Invest In 2019: China Metro-Rural Holdings Limited(CNR)

Advisors’ Opinion:

  • [By Shane Hupp]

    Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp cut its position in Canadian National Railway (NYSE:CNI) (TSE:CNR) by 21.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,956,400 shares of the transportation company’s stock after selling 522,300 shares during the period. Canadian National Railway accounts for about 1.7% of Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s investment portfolio, making the stock its 7th biggest position. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp owned 0.27% of Canadian National Railway worth $184,215,000 at the end of the most recent reporting period.

  • [By Max Byerly]

    Canadian National Railway (NYSE:CNI) (TSE:CNR) – Cormark raised their Q3 2018 earnings per share (EPS) estimates for Canadian National Railway in a research report issued to clients and investors on Tuesday, April 10th. Cormark analyst D. Tyerman now expects that the transportation company will post earnings per share of $1.15 for the quarter, up from their previous estimate of $1.14.

  • [By Stephan Byrd]

    Brokerages expect Canadian National Railway (NYSE:CNI) (TSE:CNR) to announce earnings of $1.03 per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Canadian National Railway’s earnings, with the highest EPS estimate coming in at $1.10 and the lowest estimate coming in at $0.97. Canadian National Railway reported earnings of $1.00 per share in the same quarter last year, which would indicate a positive year over year growth rate of 3%. The business is scheduled to issue its next quarterly earnings report on Tuesday, July 24th.

Best Canadian Stocks To Invest In 2019: Canadian National Railway Company(CNI)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Canadian National Railway (CNI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Shares of Canadian National Railway (TSE:CNR) (NYSE:CNI) have been given an average recommendation of “Buy” by the eleven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is C$109.36.

  • [By Motley Fool Staff]

    Canadian National Railway Co (NYSE:CNI)Q1 2018 Earnings Conference CallApril 23, 2018, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Best Canadian Stocks To Invest In 2019: Safeway Inc.(SWY)

Advisors’ Opinion:

  • [By Logan Wallace]

    Stornoway Diamond (TSE:SWY) is scheduled to post its quarterly earnings results before the market opens on Tuesday, August 14th.

    Stornoway Diamond (TSE:SWY) last announced its earnings results on Tuesday, May 15th. The company reported C($0.01) EPS for the quarter. Stornoway Diamond had a negative net margin of 6.15% and a negative return on equity of 1.78%. The business had revenue of C$55.95 million for the quarter.

  • [By Jim Robertson]

    Large and small cap junior miners have long been interested in the region due to Goldcorp’s Éléonore mine being located in the heart of the territory along with the Troilus mine (which has produced over 2 million ounces of gold from 1997-2010 and is estimated to have another remaining 2 million ounces of reserves). The Otish Mountains area has also attracted attention following the discovery of diamonds by Stornoway Diamond Corporation (TSX: SWY) at their Renard diamond mine (projected to produce 1.5-2 millions carats per year).

  • [By Jim Robertson]

    In addition, Goldcorp’s (NYSE: GG) Éléonore mine in the heart of the territory along with the Troilus mine (which produced over 2 million ounces of gold from 1997-2010 and is estimated to have another remaining 2 million ounces of reserves) are helping to maintain the interest of junior exploration companies in nearby properties. The same can be said about the Otish Mountains area following the discovery of diamonds by Stornoway Diamond Corporation (TSX: SWY) at their Renard diamond mine which is projected to produce 1.5-2 millions carats per year.

Best Canadian Stocks To Invest In 2019: Patni Computer Systems Limited(PTI)

Advisors’ Opinion:

  • [By Chris Lange]

    Proteostasis Therapeutics Inc. (NASDAQ: PTI) saw its shares slide early on Thursday after the company reported that it had positive data from its early stage trial in cystic fibrosis (CF). These results come from the firm’s ongoing Phase 1 dosing study of PTI-801 in CF patients on background Orkambi (lumacaftor/ivacaftor) therapy.

Leave a Reply

Your email address will not be published. Required fields are marked *